Compare PROP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | CGTX |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.6M | 110.8M |
| IPO Year | 2008 | 2021 |
| Metric | PROP | CGTX |
|---|---|---|
| Price | $1.10 | $1.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $6.75 | $3.33 |
| AVG Volume (30 Days) | ★ 5.4M | 991.1K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 49.06 | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $81.83 | N/A |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $1.08 | $0.22 |
| 52 Week High | $4.68 | $3.83 |
| Indicator | PROP | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.17 | 56.53 |
| Support Level | N/A | $1.19 |
| Resistance Level | $1.93 | $1.36 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 6.52 | 53.57 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).